Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma

被引：2
|
作者：
Hamlin, Paul A. [1 ,2 ,3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Basking Ridge Med Oncol Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Div Hematol Oncol, Dept Med, New York, NY 10065 USA
[3] New York Presbyterian Hosp, Dept Med, Weill Cornell Med Coll, New York, NY 10032 USA
来源：
LANCET ONCOLOGY | 2016年 / 17卷 / 08期
关键词：
D O I：
10.1016/S1470-2045(16)30157-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1023 / 1025
页数：4
相关论文
共 50 条
  • [41] A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A plus B study)
    Rummel, Mathias J.
    Janssens, Ann
    MacDonald, David
    Keating, Mary-Margaret
    Zaucha, Jan M.
    Davis, Jaclyn
    Lasher, Janet
    Pisal, Chaitali Babanrao
    Izquierdo, Miguel
    Friedberg, Jonathan W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (06) : 1123 - 1133
  • [42] Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US
    Guzauskas, Gregory F.
    Masaquel, Anthony
    Reyes, Carolina
    Bernaards, Coen
    Krivasi, Tania
    Veenstra, David L.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (10) : 960 - 967
  • [43] COST-EFFECTIVENESS OF OBINUTUZUMAB PLUS BENDAMUSTINE AND FOLLOWED BY OBINUTUZUMAB MAINTENANCE THERAPY IN CHINESE PATIENTS WITH RELAPSE AND REFRACTORY FOLLICULAR LYMPHOMA
    Ma, J.
    Zhen, B.
    Xia, Y.
    Gong, Q.
    Li, Y.
    Chen, W.
    VALUE IN HEALTH, 2022, 25 (12) : S84 - S84
  • [44] AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
    Leonard, John P.
    Trneny, Marek
    Izutsu, Koji
    Fowler, Nathan H.
    Hong, Xiaonan
    Zhu, Jun
    Zhang, Huilai
    Offner, Fritz
    Scheliga, Adriana
    Nowakowski, Grzegorz S.
    Pinto, Antonio
    Re, Francesca
    Fogliatto, Laura Maria
    Scheinberg, Phillip
    Flinn, Ian W.
    Moreira, Claudia
    Cabecadas, Jose
    Liu, David
    Kalambakas, Stacey
    Fustier, Pierre
    Wu, Chengqing
    Gribben, John G.
    Calaminici, Maria
    Copie-Bergman, Christiane
    Lopez-Guillermo, Armando
    O'Connor, Owen
    Williams, Michael
    Suciu, Stefan
    Levine, Benjamin
    Kern, Julie
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1188 - +
  • [45] A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma
    Khan, Khuda D.
    Emmanouilides, Christos
    Benson, Don M., Jr.
    Hurst, Deborah
    Garcia, Pablo
    Michelson, Glenn
    Milan, Sandra
    Ferketich, Amy K.
    Piro, Lawrence
    Leonard, John P.
    Porcu, Pierluigi
    Eisenbeis, Charles F.
    Banks, Amy L.
    Chen, Lei
    Byrd, John C.
    Caligiuri, Michael A.
    CLINICAL CANCER RESEARCH, 2006, 12 (23) : 7046 - 7053
  • [46] The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Friedberg, Jonathan W.
    Vose, Julie M.
    Kelly, Jennifer L.
    Young, Faith
    Bernstein, Steven H.
    Peterson, Derick
    Rich, Lynn
    Blumel, Susan
    Proia, Nicole K.
    Liesveld, Jane
    Fisher, Richard I.
    Armitage, James O.
    Grant, Steven
    Leonard, John P.
    BLOOD, 2011, 117 (10) : 2807 - 2812
  • [47] Pharmacokinetics of Bendamustine Hydrochloride in Chinese Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Refractory to Rituximab Treatment
    Han, Xiaohong
    Li, Ning
    Song, Yuan-Yuan
    Hellriegel, Edward
    Robertson, Philmore
    Shi, Yuan-Kai
    BLOOD, 2016, 128 (22)
  • [48] Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis
    Zhang, Peng-Fei
    Xie, Dan
    Wen, Feng
    Li, Qiu
    CANCER MEDICINE, 2020, 9 (15): : 5312 - 5319
  • [49] Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Rafia, Rachid
    Pandor, Abdullah
    Davis, Sarah
    Stevens, John W.
    Harnan, Sue
    Clowes, Mark
    Sorour, Youssef
    Cutting, Robert
    PHARMACOECONOMICS, 2018, 36 (10) : 1143 - 1151
  • [50] Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Rachid Rafia
    Abdullah Pandor
    Sarah Davis
    John W. Stevens
    Sue Harnan
    Mark Clowes
    Youssef Sorour
    Robert Cutting
    PharmacoEconomics, 2018, 36 : 1143 - 1151
12345